NVSEF
Overvalued by 2% based on the discounted cash flow analysis.
Market cap | $216.93 Billion |
---|---|
Enterprise Value | $234.52 Billion |
Dividend Yield | $3.3 (0.0%) |
Earnings per Share | $7.34 |
Beta | 0.0 |
Outstanding Shares | 2,189,930,497 |
Avg 30 Day Volume | 16,045 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 14.23 |
---|---|
PEG | 82.61 |
Price to Sales | 4.8 |
Price to Book Ratio | 5.33 |
Enterprise Value to Revenue | 5.15 |
Enterprise Value to EBIT | 22.14 |
Enterprise Value to Net Income | 15 |
Total Debt to Enterprise | 0.12 |
Debt to Equity | 0.69 |
No data
No data
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...